CTLA4 and acute kidney injury: A recent multicenter study identified three independent risk factors for development of ICI-AKI: 1) concomitant use of PPIs; 2) combination treatment with anti–CTLA-4 and anti–PD-1/PD-L1 agents; and 3) lower baseline eGFR (48).